During the last session, Sio Gene Therapies Inc. (NASDAQ:SIOX)’s traded shares were 1.72 million, with the beta value of the company hitting 1.90. At the end of the trading day, the stock’s price was $0.25, reflecting an intraday loss of 1.44% or $0.0. The 52-week high for the SIOX share is $2.95, that puts it down -1080.0 from that peak though still a striking 0.0% loss since the share price plummeted to a 52-week low of $0.25. The company’s market capitalization is $18.56M, and the average trade volume was 461.20K shares over the past three months.
Sio Gene Therapies Inc. (SIOX) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 1.40. SIOX has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.2.
Sio Gene Therapies Inc. (NASDAQ:SIOX) trade information
Sio Gene Therapies Inc. (SIOX) registered a 1.44% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.44% in intraday trading to $0.25 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -11.53%, and it has moved by -57.02% in 30 days. Based on these gigs, the overall price performance for the year is -87.73%.
The consensus price target of analysts on Wall Street is $3.95, which implies an increase of 93.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.80 and $7.00 respectively. As a result, SIOX is trading at a discount of -2700.0% off the target high and -220.0% off the low.
Sio Gene Therapies Inc. (SIOX) estimates and forecasts
Statistics show that Sio Gene Therapies Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Sio Gene Therapies Inc. (SIOX) shares have gone down -86.84% during the last six months, with a year-to-date growth rate less than the industry average at -23.81% against -0.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 44.00%. While earnings are projected to return 78.80% in 2022.
Sio Gene Therapies Inc. is due to release its next quarterly earnings between February 07 and February 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sio Gene Therapies Inc. (NASDAQ:SIOX)’s Major holders
Sio Gene Therapies Inc. insiders own 25.68% of total outstanding shares while institutional holders control 29.41%, with the float percentage being 39.57%. Suvretta Capital Management, LLC is the largest shareholder of the company, while 57 institutions own stock in it. As of Dec 30, 2021, the company held over 5.91 million shares (or 8.02% of all shares), a total value of $7.63 million in shares.
The next largest institutional holding, with 3.0 million shares, is of Rubric Capital Management LP’s that is approximately 4.07% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $3.87 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sio Gene Therapies Inc. (SIOX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.38 million shares. This amounts to just over 1.87 percent of the company’s overall shares, with a $1.78 million market value. The same data shows that the other fund manager holds slightly less at 0.6 million, or about 0.81% of the stock, which is worth about $0.77 million.